Optimisation of the method was achievedusing LiChrospher RP 8 250mm 4.6mm ; 5 mm column ,gradient elu-tion with Sodium dihydrogen phosphate buffer solution pH 5 and Ace-tonitrile mixed in mobile phase A and mobile phase B,with a flow ratefrom 1.8 to 2 ml/min.The detection is at 210 nm, temperature of thecolumn is 50degC,injection volume of 20 ml.The first condition for systemsuitability to be achieved is :- The chromatogram obtained from the Lisinopryl dihydrate for per-formance test is similar to the chromatogram supplied with Lisinopryldihydrate for performance test CRS in which the peaks due to impu-rity A and Impurity E fall on either side of the peak due to lisinopril.Thesecond condition is:29PHARMACEUTICAL ANALYSIS / QUALITY ASSURANCE / REGULATORY AFFAIRS poster presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONMakedonski farmatsevtski bilten 57 (dodatok), 2011- the peak-to-valley ratio: minimum 9 between Impurity A and Lisino-pril and minimum 9 between Lisinopril and Impurity E. Complete val-idation of the method is performed ,even resolution and not only p/vis achieved between Impurity A and Lisinopril of about 3.42 and be-tween Lisinopril and Impurity E of about 3.74.The relative retentiontimes of the known impurities with reference to Lisinopril peak werecalculated and are as follows: Impurity B 0.70; Impurity A 0.79; Impu-rity E 0.32; Impurity F 2.26;Impurity D 2.63; Impurity C 2.85.The cor-rection factor for each impurity is also incorporated in the methodand their values are: 1 for Impurity B; 0.89 for Impurity A;1.18 for Im-purity E; 2.37 for Impurity F; 1.30 for Impurity D; 1.27 for Impurity C.From our conducted stability studies for Skopryl(Lisinopril) tablets wehave concluded that our products is very stable during its shelf life.The both methods are equally reliable for analyzing the related anddegradation products. The conclusion is that the second method isadded to our internal standard for analysis of Skopryl tablets as a sec-ond additional method, only in case of need for identification of anyunknown impurities greater than the specification limits found withthe first method.REFERENCES1. British Pharmacopoeia 20102. European Pharmacopoeia 6.03. Drug Master File-Ranbaxy Laboratories Ltd4. Drug Master File-Aurobindo Pharma Ltd5. David M Blesner, Validating chromatographic methods,a practical guide SPOREDBA NA DVE HPLC METODI ZAANALIZA NA SRODNI I DEGRADATsIONIPRODUKTI VO SKOPRIL (LIZINOPRIL)TABLETITsveta Dolikjoska, Dafinka Damchevska, BlagitsaSamarova-Stoev, Ana Aleksandrikj, KhristinaBabunovskaAD Alkaloid - Skopje , Lizinopril spagja vo grupata na inkhibitori na (AKE) Angiotenzinkonvertirachki enzim koi primarno se koristat vo tretman nakhipertenzija, kongestivna srtseva slabost i srtsevi udari,aistotaka vo preventsija na renalnite i retinalnite komplikatsiikaj bolnite od shekjerna bolest. Lizinoprilot e lizinski analogna enalaprilot. Toj e khidrofilna supstantsa ,ima dolg poluzhivoti tkivna penetratsija i ne se metabolizira vo tsrniot drob.Nasha tsel e da gi sporedime dvete razlichni HPLC metodi zaodreduvanje na srodnite i degradatsioni produkti na Lizi no pri -lot vo nashiot gotov proizvod -Skopril tableti. Metodata za srodni i degradatsioni produkti vo Lizinopriltableti spored Britanska farmakopeja-adaptirana poradipodobro khromatografiranje za nasha interna upotreba e ed no stav -na izokratska metoda. Metodata se raboti na LiChrospher RP 8kolona so dimenzii 250mm x 4 mm 5 m, mobilnata faza e meshavina od 70% pufer so pH vrednost 2(Kalium dikhidrogen fosfat i Natrium kheksan sulfonat ) i 30%Atsetonitril, protokot e 1 ml vo minuta,detektsijata na 215 nm,temperaturata na kolonata e 40degC,a volumenot na injektiranje 20 ml.Rastvoruvachot e meshavina od 80% voda i 20% Metanol.Vospostavenparametar za soodvetnost na sistemot e rezolutsija pomegjupikovite koi poteknuvaat od Lisinopril diketopiperazine i Lisinopril,a uslovot koj treba da se postigne i e postignat e :Rezolutsijatapomegju tie dva pika da ne bide pomala od 5. So baranjata na ovaamonografija se identifikuva i kvantifikuva samo edno poznatoonechistuvanje: Lisinopril diketopiperazine koe se detektira kakoeden pik a vsushnost e ratsemska smesa od S,S,S diketopiperazinili Onechistuvanje C i R,S,S diketopiperazin ili Onechistuvanje D.Ovie se samo dve od poznatite onechistuvanja od vkupno sheste koise deklarirani vo Evropskata Farmakopeja:>> Onechistuvanje A- Onechistuvanje koe poteknuva od proiz vod -ni ot protses>> Onechistuvanje B- Onechistuvanje koe poteknuva od pro i z vod -ni ot protses>> Onechistuvanje C - S,S,S diketo piperazin - Onechistuvanje koepoteknuva od proizvodniot protses i degradatsionoonechistuvanje>> Onechistuvanje D- R,S,S diketo piperazin - Onechistuvanje koepo teknuva od proizvodniot protses i degradatsiono one chi st -u vanje>> Onechistuvanje E - Lizinopril R,S,S-izomer-Onechistuvanjekoe poteknuva od proizvodniot protses>> Onechistuvanje F- tsiklokheksil analog- Onechistuvanje koe po -te k nuva od proizvodniot protsesToa e prichinata poradi koja razvivme i validiravme dopolnitelnasoodvetna interna metoda adaptirana po monografijata odEvropska farmakopeja za nashiot gotov proizvod Skopril tabletiod 5,10 i 20 mg. Novata metoda ima sposobnost da ja razdvoiaktivnata supstantsa od site bliski srodni i degradatsionisupstantsi,tie da se identifikuvaat i soodvetno da sekvantifikuvaat.Optimizatsija na metodata postignavme koristejkjiLiChrospher RP 8 kolona so dimenzi 250mm kh 4.6mm 5 mm, sogradientno eluiranje koristejkji Natrium dikhidrogen fosfatenpuferen rastvor so pH 5 i Atsetonitril izmeshani vo Mobilnafaza A i Mobilna faza V.Protokot se menuva od 1,8 do 2 ml vominuta,detektsijata e na 210nm, temperaturata na kolonata e50degC,volumenot na injektiranje e 20 ml.Prviot uslov za soodvetnostna sistemot koj treba da se postigne e :- Xromatogramot dobien so khromatografiranje na referentniotstandard Lizinopril dikhidrat za performans test e slichen sokhromatogramot dostaven za toj standard od Evropska Farmakopejakade shto pikovite od Onechistuvanje A i Onechistuvanje E se naogjaatna obete strani od pikot koj poteknuva od Lizinoprilot.Vtoriot uslov e:- peak-to-valley odnos: minimum 9 pomegju Onechistuvanje A i Li zi no -pril i minimum 9 pomegju Lizinopril i Onechistuvanje E. Napravenae kompletna validatsija na metodata,duri i rezolutsija namesto p/vodnos e postignata od okolu 3,42 megju Onechistuvanje A iLizinopril i okolu 3,74 megju Lizinopril i Onechistuvanje E. Pre sme -tani se i relativnite retentsioni vreminja na poznatite one chi stuvanjavo odnos na pikot na Lizinopril koi iznesuvaat: One chistuvanje B 0.70;Onechistuvanje A 0.79; Onechistuvanje E 0.32; Onechistuvanje F 2.26;Onechistuvanje D 2.63; Onechistuvanje C 2.85.Korektsioni faktori zapresmetuvanje na vrednostite na sekoe onechistuvanje se isto takavklucheni vo metodata.Nivnite vrednosti se: 1 za onechistuvanje B, 0,89za Onechistuvanje A, 1,18 za One chi stu va nje E, 2,37 za onechistuvanje F,1,30 za onechistuvanje D i 1,27 za onechistuvanje C.30Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKI ANALIZI / OBEZBEDUVANjE KVALITET / REGULATIVA poster prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOOd sledenjeto na stabilnost na ovoj preparat, od studiite zastabilnost e zaklucheno deka nashiot proizvod e mnogu stabilen zavreme na negoviot rok na traenje. Dvete metodi se podednakvosoodvetni za analiziranje na srodnite i degradatsioni produkti.Zakluchokot e deka vtorata metoda e dodadena samo kakodopolnitelna metoda na nashiot interen standard -Analitichka pro -tse du ra za analiza na srodni i degradatsioni produkti vo Skopril(Lizinopril) tableti, samo vo sluchaj da e potrebna identifikatsijana bilo koe nepoznato poedinechno onechistuvanje nad dozvolenitespetsifikatsioni granitsi dobieno so analiziranje na proizvodotso prvata metoda.REFERENTsI1. Britanska Farmakopeja 20102. Evropska Farmakopeja 6.03. Drug Master File-Ranbaxy Laboratories Ltd4. Drug Master File-Aurobindo Pharma Ltd5. David M Blesner, Validatsija na khromatografski metodi,praktichen vodichHPLC METHOD FOR DETERMINATION OFRELATED AND DEGRADATION SUBSTANCESIN AMLODIPINE ALKALOID(r) TABLETSM. Dobrkovic, V. Dubrova-Koceva, S. Naumovska, N.Stojanovska, H. BabunovskaQuality Control department, AD Alkaloid-Skopje, Pharmaceutical,Chemical and Cosmetic Company, A. Makedonski 12, Skopje, MacedoniaAmlodipine is a dihydropyridine calcium antagonist or long-acting cal-cium channel blocker, widely used in treatment of hypertension andcoronary artery disease. The use of Amlodipine as a hypertension drugis highly common, as it acts as a peripheral arterial vasodilator, on theother hand its precise use in treatment of angina is not fully delin-eated.The purpose of our work was to develop and validate a reliable andsensitive HPLC method for quantitative determination of related anddegradation substances in our finish product Amlodipine tablets.The optimal chromatographic separation was achieved using a YMCPack ODS AQ column, 250 x 4,6 mm; 5mm, with mobile phase con-taining mixture of phosphatic buffer pH = 3,5 (mobile phase A) andmethanol (mobile phase B), with gradient elution mode and constantflow rate, 1 ml/min. UV detection was at 237 nm, room temperatureof the column and injection volume of 20 ml . These chromatographic conditions allowed separation of Amlodipinefrom its related and degradation impurities A, B, E, G, which areformed during the process of synthesis, Impurity D which is a degra-dation product generated due to oxidation of amlodipine base andImpurity F . The relative retention times of Impurities A, B, D, E, F, andG were calculated according to the retention time of Amlodipine andare given in addition: 7.0, 3.9, 0.7, 1.3, 0.8, and 2.8, respectively. The res-olution between benzene sulfonate and Impurity D, and Amlodipineand Impurity F in the resolution solution were 2.34 and 4.25, respec-tively and system suitability criteria were met.The identification of the impurities was made by comparison of thechromatograms gained from standard for peak identification CRS andspiked standard with impurities.Validation of the HPLC method was performed with concentration ofthe amlodipine standard 0,005mg/ml, as a target concentration thatcorrespondents to 0,5 % of the test solution. To perform method vali-dation, results obtained by the HPLC method were compaired via speci-ficity, linearity and range, accuracy, precision, robustness, quantitationand detection limit, filter retention studies and stability of solution.Our method differs from the method given in the EuropeanPharmacopoeia for determination of impurities in Amlodipine. Given allthe facts above, our study provided enough evidence that this methodis applicable for determination of the same impurities and is applied forthe same purpose in routine quality control and stability studies.REFERENCE1. Validating Chromatographic methods, David M. Bliesnerhttp://www.drugs.com/amlodipine.html2. Practical HPLC Method Development, 2nd Edition., Lloyd R. Snyder, Joseph J. Kirkland, Joseph L. Glajch3. HPLC Method Development for Pharmaceuticals, Volume 8 (Separation Scienceand Technology) 2007, Satinder Ahuja, Henrik Rasmussen4. Introduction to Modern Liquid Chromatography, 2010, Lloyd R. Snyder, Joseph J. Kirkland, Jonh W. DolanHPLC METODA ZA ODREDUVANjE NASRODNI I DEGRADATsIONI PRODUKTIVO AMLODIPINE ALKALOID(r) TABLETIM. Dobrkovikj, V. Dubrova-Kotseva, S. Naumovska,N.Stojanovska, Kh. BabunovskaKontrola na Kvalitet, A.D Alkaloid-Skopje, Farmatsevtska, Khe m i skai Kozmetichka industrija, A. Makedonski 12, Skopje, MakedonijaAmlodipin e dikhidropiridinski kaltsium antagonist odnosnoblokator na kaltsiumovite kanali so prodolzheno dejstvo, koj imashiroka primena vo tretmanot na khipertenzijata i koronarnitearteriski zaboluvanja.